A phase 3 randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

被引：0

作者：

Bendell, Johanna C.

Starodub, Alexander

Wainberg, Zev A.

Wu, Meihua

Werner, Douglas

Maltzman, Julia D.

Shah, Manish A.

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Tennessee Oncol PLLC, Nashville, TN USA

[3] Parkview Hlth, Parkview Canc Inst, Ft Wayne, IN USA

[4] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[5] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS4132

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4132

引用

页数：2